Consequently, DYRK1A has been considered as a potential therapeutic target of neurodegenerative diseases such as Alzheimer’s disease (AD) and Down’s syndrome (DS) [3]. Here, DYRK1A is linked to early-onset autosomal dominant Alzheimer disease.